Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

NICE finds more SMA patients eligible for £75,000 a vial drug

May 4, 2021
Manufacturing and Production, Sales and Marketing NICE, sma

NICE has announced that more people with the rare genetic disorder spinal muscular atrophy (SMA) are to benefit from nusinersen, …

News

NICE to join GetReal Institute alongside nine key healthcare players

April 28, 2021
Research and Development EU, NICE, rwe

NICE has announced it will join with nine other organisations to form the GetReal Institute, a not-for-profit multi-stakeholder enterprise, as …

News

NICE updates guidelines on atrial fibrillation based on new evidence

April 27, 2021
Manufacturing and Production NICE

NICE has updated its guideline on the diagnosis and management of atrial fibrillation (AF) based on new evidence found since …

News

Novartis multiple sclerosis treatment recommended by NICE

April 20, 2021
Manufacturing and Production NICE, Novartis, multiple sclerosis, pharma, pharma news

NICE have recommenced Novartis’ ofatumumab (Kesimpta) for the treatment of relapsing remitting MS (RRMS) in adult patients for use on …

News

NICE launch ambitious five-year patient access strategy

April 19, 2021
Sales and Marketing NICE

NICE has unveiled its five-year plan to speed up patients’ access to the latest and most effective treatments with increased …

News
nhs_old_hospital_1

First approved C5 complement inhibitor recommended by NICE for NHS use

April 15, 2021
NHS, NICE

NICE has recommended Ultomiris (ravulizumab) for use in the NHS for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in adult …

News

NICE recommends CBT, acupuncture, and anti-depressants for chronic pain

April 7, 2021
Research and Development NICE, antidepressant, chronic pain

A new NICE guideline on the assessment and management of chronic primary pain does not recommend the prescription of painkillers, …

News

NICE recommends Kineret for Still’s disease treatment

April 1, 2021
NICE

Sobi has today announced a NICE recommendation of Kineret (anakinra) as a first-line biologic therapeutic option for still’s disease, including …

News
1558469633615

The Truth Behind the £1.8 Million Drug

March 31, 2021
Manufacturing and Production FDA, NHS, NICE

As NICE approves the most expensive drug ever for use by the NHS, Jack Goddard takes a look at drug …

Feature

NICE recommends new triple therapy for multiple myeloma patients

March 19, 2021
Medical Communications NHS England, NICE, oncology

A new second line triple therapy is to be offered to NHS patients in England with multiple myeloma, following a …

News

AstraZeneca & MSD ovarian cancer drug combination approved by NICE

March 19, 2021
Medical Communications AstraZeneca, MSD, NICE, oncology

A new precision drug combination, olaparib with bevacizumab, will now be available on the Cancer Drugs Fund (CDF) for ovarian …

News
index_ph001

NICE recommends Daiichi Sankyo’s cholesterol-lowering treatments for NHS England use

March 18, 2021
Daiichi Sankyo, NICE, cholesterol

NICE has recommended Daiichi Sankyo’s bempedoic acid and bempedoic acid/ezetimibe for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed …

News

NICE recommends £1.79m gene therapy for spinal muscular atrophy in babies

March 8, 2021
Sales and Marketing NICE, spinal muscular atrophy

NICE is set to approve a new and potentially curative one-off gene therapy for babies with the rare genetic disorder …

News

NICE recommends Novartis’ ribociclib in combination with fulvestrant for breast cancer

February 26, 2021
Medical Communications Cancer, NICE, Novartis

NICE has recommended Novartis’ Kisqali (ribociclib) in combination with fulvestrant for women with prior endocrine therapy. It will be made …

News

NICE issues draft guidance recommending sapropterin for PKU in children

February 25, 2021
BioMarin, NICE, PKU

NICE has issued draft guidance which recommends BioMarin’s Kuvan (sapropterin) at a dose of up to 10 mg/kg for treating phenylketonuria …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026